Alligator Bioscience AB (publ) Interim report January-March 2019
First patient dosed in Phase I clinical study of ATOR-1015 Significant events January-March• First patient dosed in Phase I clinical study o ...
Alligator Bioscience AB Interim Report January-September 2018
The science behind the Nobel Prizes in Medicine and Chemistry constitutes the core in Alligator’s research and development. Significant even ...
Alligator Bioscience AB Interim Report January-March 2018
Positive preclinical data for ATOR-1015 "Data provide strong support for our claims that ATOR-1015 is a next generation bispecific CTLA- ...
Alligator Bioscience AB Full Year Report 2017
The Janssen collaboration continues, milestone payment of 6 MUSD triggered Significant events, October-December • Alligator Bioscience recor ...
Change in number of shares and votes in Alligator Bioscience AB (publ)
Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) announced today that the number of shares and votes in Alligator Bios ...